Kyverna Therapeutics/$KYTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kyverna Therapeutics
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Ticker
$KYTX
Sector
Primary listing
Employees
130
Headquarters
Website
KYTX Metrics
BasicAdvanced
$566m
-
-$3.64
2.64
-
Price and volume
Market cap
$566m
Beta
2.64
52-week high
$13.67
52-week low
$2.05
Average daily volume
1.1m
Financial strength
Current ratio
7.755
Quick ratio
7.653
Long term debt to equity
10.79
Total debt to equity
12.499
Interest coverage (TTM)
-347.29%
Profitability
EBITDA (TTM)
-168.028
Management effectiveness
Return on assets (TTM)
-35.47%
Return on equity (TTM)
-64.67%
Valuation
Price to book
2.43
Price to tangible book (TTM)
2.43
Price to free cash flow (TTM)
-2.673
Free cash flow yield (TTM)
-37.42%
Free cash flow per share (TTM)
-3.499
Growth
Earnings per share change (TTM)
9.60%
3-year earnings per share growth (CAGR)
-61.41%
What the Analysts think about KYTX
Analyst ratings (Buy, Hold, Sell) for Kyverna Therapeutics stock.
KYTX Financial Performance
Revenues and expenses
KYTX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kyverna Therapeutics stock?
Kyverna Therapeutics (KYTX) has a market cap of $566M as of May 10, 2026.
What is the P/E ratio for Kyverna Therapeutics stock?
The price to earnings (P/E) ratio for Kyverna Therapeutics (KYTX) stock is 0 as of May 10, 2026.
Does Kyverna Therapeutics stock pay dividends?
No, Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders as of May 10, 2026.
When is the next Kyverna Therapeutics dividend payment date?
Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Kyverna Therapeutics?
Kyverna Therapeutics (KYTX) has a beta rating of 2.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.